Epsium Enterprise schedules extraordinary general meeting for shareholders

Samsung just scored a chip deal with Tesla, but don’t get it twisted—this isn’t some sneak attack on Nvidia’s AI dominance. Instead, it’s a reminder that Samsung’s semiconductor division still has serious muscle in the foundry game, even as rivals like TSMC hog the spotlight.

Editor’s Note: While everyone’s obsessing over Nvidia’s AI chips, this deal quietly underscores Samsung’s resilience in a cutthroat market. For Tesla, diversifying suppliers is smart business, and for Samsung, it’s proof they’re still a player—not just an afterthought. That’s a win worth noticing.

The Trump administration is considering a major shake-up of the U.S. patent system by introducing fees tied to the value of patents. The idea, floated by Commerce Department officials, aims to boost government revenue but could spark pushback from businesses worried about higher costs and complexity.

Editor’s Note: Patents are the lifeblood of innovation—especially for tech and pharma companies—so tinkering with how they're taxed is a big deal. If the government starts charging fees based on patent value, it could hit R&D-heavy industries hard, potentially stifling innovation or triggering legal battles. On the flip side, the feds argue it’s a way to fund the system more fairly. Either way, businesses will be watching closely.

A once-promising medical and dental device company, known for its trendy and innovative approach, has filed for Chapter 11 bankruptcy. This comes as a surprise given its earlier hype about revolutionizing the industry.

Editor’s Note: This isn’t just another corporate collapse—it’s a setback for an industry that’s hungry for fresh ideas. The company’s failure raises questions about whether flashy branding can outlast real-world financial pressures, especially in the competitive medical tech space. Investors and consumers alike will be watching to see what this means for other disruptors in the sector.

Bank of America analysts are flagging an unexpected risk in the economic outlook—not just a rebound, but a potential boom under Trump-era policies. They suggest markets might be underestimating how strong growth could get, which could throw off current forecasts.

Editor’s Note: Usually, analysts worry about downturns, but this flips the script—what if things go too well? If growth surges beyond expectations, it could disrupt everything from inflation to interest rates, forcing investors and policymakers to scramble. It’s a reminder that "too hot" can be just as tricky as "too cold."

This article dives into the real-world impact of U.S. tariffs—those taxes on imported goods you’ve probably heard about in trade wars. Turns out, it’s not foreign companies footing the bill; American businesses and consumers often end up paying more, whether through higher prices or squeezed profit margins. The piece also tracks where that tariff money actually goes (spoiler: mostly the U.S. Treasury) and why the economic ripple effects might not be what politicians promise.

Editor’s Note: Tariffs sound simple—tax imports, protect local jobs—but the reality’s messier. This story matters because it peels back the curtain on who really bears the cost (hint: it’s usually you at the checkout line) and whether these policies deliver on their hype. With global trade tensions flaring up again, understanding tariffs is key to cutting through the political noise.